Breakout Stocks of Week 38
NASDAQ was down last week (week 37) by -1.61% ending at 15,115.49 points after falling -248.03 points during the week. Our system has detected some possible breakout stocks for the following week and these should be on your watchlist. These are the stocks that are bouncing up with good increase in volume and are likely to do good in short term. One of these stocks are Daré Bioscience, Inc. NASDAQ:DARE. This stock has had a buy signal since Aug 23, 2021 when the price was $1.62 and is so far up 1.85% to $1.65. Some other companies are on our watchlist to, among these are Verve Therapeutics, Inc. NASDAQ:VERV First Trust TCW Opportunistic Fixed Income ETF NASDAQ:FIXD Winmark Corporation NASDAQ:WINA and Nuveen AMT-Free Municipal Value Fund NYSE:NUV which all got a breakout pattern emerging.
| Date | Company | Price | Week 38 |
|---|---|---|---|
| Daré Bioscience, Inc. | $1.65 | $1.77 | 7.27% |
| Verve Therapeutics, Inc. | $73.99 | $59.88 | -19.07% |
| First Trust Tcw Opportunistic Fixed Income Etf | $54.05 | $54.03 | -0.0370% |
| Winmark Corporation | $204.35 | $213.91 | 4.68% |
| Nuveen Amt-free Municipal Value Fund | $11.40 | $11.65 | 2.19% |
The Daré Bioscience, Inc. stock price fell by -3.51% on the last day (Friday, 10th Sep 2021) from $1.71 to $1.65. During the last trading day the stock fluctuated 4.24% from a day low at $1.65 to a day high of $1.72. The price has been going up and down for this period, and there has been a -4.62% loss for the last 2 weeks. Volume has increased on the last day by 704 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 2 million shares were bought and sold for approximately $3.51 million.
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Daré Bioscience, Inc. stock to perform well in the short-term.
About Daré Bioscience, Inc.:
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.
The Verve Therapeutics, Inc. stock price gained 1.00% on the last trading day (Friday, 10th Sep 2021), rising from $73.26 to $73.99. During the last trading day the stock fluctuated 3.03% from a day low at $73.33 to a day high of $75.55. The price has risen in 6 of the last 10 days and is up by 12.43% over the past 2 weeks. Volume fell on the last day by -77 thousand shares and in total, 295 thousand shares were bought and sold for approximately $21.86 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
On Apr 08, 2024, it was reported that H.C. Wainwright gave VERV a "Buy" grade with a "initialise" action.
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Verve Therapeutics, Inc. stock to perform well in the short-term.
About Verve Therapeutics, Inc.:
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
The First Trust TCW Opportunistic Fixed ETF price fell by -0.129% on the last day (Friday, 10th Sep 2021) from $54.12 to $54.05. During the last trading day the ETF fluctuated 0.333% from a day low at $54.01 to a day high of $54.19. The price has risen in 6 of the last 10 days and is up by 0.33% over the past 2 weeks. Volume fell on the last day along with the ETF, which is actually a good sign as volume should follow the ETF. On the last day, the trading volume fell by -73 thousand shares and in total, 308 thousand shares were bought and sold for approximately $16.62 million.
Several short-term signals are positive and we conclude that the current level may hold a buying opportunity, as there is a fair chance for First Trust TCW Opportunistic Fixed ETF to perform well in the short-term period.
The Winmark Corporation stock price gained 1.66% on the last trading day (Friday, 10th Sep 2021), rising from $201.01 to $204.35. During the last trading day the stock fluctuated 3.00% from a day low at $202.00 to a day high of $208.06. The price has risen in 6 of the last 10 days and is up by 0.56% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 1 thousand more shares were traded than the day before. In total, 10 thousand shares were bought and sold for approximately $2.07 million.
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Winmark Corporation stock to perform well in the short-term.
About Winmark Corporation:
Winmark Corporation, together with its subsidiaries, operates as a franchisor of retail store concepts that buy, sell, trade, and consign used merchandise primarily in the United States and Canada. The company operates through two segments, Franchising and Leasing. Its franchises retail stores operate under the Plato's Closet, Once Upon A Child, Play It Again Sports, Style Encore, and Music Go Round brand names. The company's Plato's Closet brand stores buys and sells used clothing and accessories for the teenage and young adult market; and Once Upon A Child brand stores buys and sells used and new children's clothing, toys, furniture, equipment, and accessories primarily to parents of children ages infant to 12 years. Its Play It Again Sports brand stores buys, sells, trades in, and used and new sporting goods, equipment, and accessories for various athletic activities, such as team sports, fitness, ski/snowboard, golf, and others; Style Encore brand stores buys and sells used women's apparel, shoes, and accessories; and Music Go Round brand stores buys, sells, trades in, and used and new musical instruments, speakers, amplifiers, music-related electronics, and related accessories. In addition, the company is also involved in the middle-market equipment leasing business focusing on technology and business-essential equipment. As of February 23, 2022, it had 1,271 franchised stores, as well as offers its products online at musicgoround.com, playitagainsports.com, and style-encore.com. Winmark Corporation was incorporated in 1988 and is headquartered in Minneapolis, Minnesota.
The Nuveen AMT-Free Municipal Value Fund stock price gained 0.352% on the last trading day (Friday, 10th Sep 2021), rising from $11.36 to $11.40. During the last trading day the stock fluctuated 0.87% from a day low at $11.32 to a day high of $11.42. The price has fallen in 5 of the last 10 days and is down by -2.81% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 23 thousand more shares were traded than the day before. In total, 285 thousand shares were bought and sold for approximately $3.25 million.
Several of the signals/indicators are negative, and we believe that this will affect on the development for the next days and maybe possible weeks. However, over time, we think that today's level holds a possible buying opportunity and that the price will be higher during or at the end of this 3-month period.
About Nuveen AMT-Free Municipal Value Fund:
Nuveen Municipal Value Fund, Inc. is a closed-ended fixed income mutual fund launched by Nuveen Investments, Inc. The fund is co-managed by Nuveen Fund Advisors LLC and Nuveen Asset Management, LLC. It invests in the fixed income markets of the United States. The fund also invests some portion of its portfolio in derivative instruments. It invests in undervalued municipal securities and other related investments the income, exempt from regular federal income taxes that are rated Baa or BBB or better. It employs fundamental analysis with bottom-up stock picking approach to create its portfolio. The fund benchmarks the performance of its portfolio against the Standard & Poor's (S&P) National Municipal Bond Index. Nuveen Municipal Value Fund, Inc. was formed on April 8, 1987 and is domiciled in the United States.
Despite these candidates are looking good from a technical perspective they may not perform as expected. You should always be cautious when trading and base your decisions on more than one source of information. This does not constitute an offer or recommendation to buy or sell securities.
